404 related articles for article (PubMed ID: 33063092)
1. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept.
Szabo C; Martins V; Liaudet L
Am J Respir Cell Mol Biol; 2020 Nov; 63(5):571-590. PubMed ID: 32640172
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
4. The kynurenine pathway of tryptophan metabolism: a neglected therapeutic target of COVID-19 pathophysiology and immunotherapy.
Badawy AA
Biosci Rep; 2023 Aug; 43(8):. PubMed ID: 37486805
[TBL] [Abstract][Full Text] [Related]
5. Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Heer CD; Sanderson DJ; Voth LS; Alhammad YMO; Schmidt MS; Trammell SAJ; Perlman S; Cohen MS; Fehr AR; Brenner C
J Biol Chem; 2020 Dec; 295(52):17986-17996. PubMed ID: 33051211
[TBL] [Abstract][Full Text] [Related]
6. AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives.
Turski WA; Wnorowski A; Turski GN; Turski CA; Turski L
Restor Neurol Neurosci; 2020; 38(4):343-354. PubMed ID: 32597823
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
8. Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.
Grunewald ME; Shaban MG; Mackin SR; Fehr AR; Perlman S
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694960
[TBL] [Abstract][Full Text] [Related]
9. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
Thomas C; Ji Y; Lodhi N; Kotova E; Pinnola AD; Golovine K; Makhov P; Pechenkina K; Kolenko V; Tulin AV
EBioMedicine; 2016 Nov; 13():90-98. PubMed ID: 27727003
[TBL] [Abstract][Full Text] [Related]
10. Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Sriram CS; Jangra A; Bezbaruah BK; V AK; Sykam S
Front Biosci (Schol Ed); 2016 Jan; 8(1):123-8. PubMed ID: 26709902
[TBL] [Abstract][Full Text] [Related]
11. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
[TBL] [Abstract][Full Text] [Related]
12. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.
Capoluongo E
Biomed Pharmacother; 2020 Oct; 130():110536. PubMed ID: 32688139
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase-1: a novel therapeutic target in necrotizing enterocolitis.
Giannone PJ; Alcamo AA; Schanbacher BL; Nankervis CA; Besner GE; Bauer JA
Pediatr Res; 2011 Jul; 70(1):67-71. PubMed ID: 21399558
[TBL] [Abstract][Full Text] [Related]
15. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.
Omran HM; Almaliki MS
J Infect Public Health; 2020 Sep; 13(9):1196-1201. PubMed ID: 32534944
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis: Emerging Roles for Aryl Hydrocarbon Receptor in Orchestrating CoV-2-Related Inflammation.
Guarnieri T
Cells; 2022 Feb; 11(4):. PubMed ID: 35203299
[TBL] [Abstract][Full Text] [Related]
17. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
19. High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
Kotova E; Tulin AV
Methods Mol Biol; 2017; 1608():299-312. PubMed ID: 28695517
[TBL] [Abstract][Full Text] [Related]
20. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
